Alkermes (NASDAQ:ALKS – Get Free Report) released its quarterly earnings data on Wednesday. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70, RTT News reports. Alkermes had a net margin of 19.15% and a return on equity of 23.20%. The firm had revenue of $399.13 million during the quarter, compared to analysts’ expectations of $393.30 million. During the same period last year, the business earned $0.38 earnings per share. Alkermes’s revenue was down 35.4% compared to the same quarter last year. Alkermes updated its FY 2024 guidance to 2.800-2.800 EPS.
Alkermes Stock Down 0.6 %
Alkermes stock traded down $0.16 during midday trading on Friday, reaching $27.88. The company’s stock had a trading volume of 2,101,783 shares, compared to its average volume of 1,905,860. Alkermes has a fifty-two week low of $22.01 and a fifty-two week high of $32.88. The company has a quick ratio of 2.77, a current ratio of 3.16 and a debt-to-equity ratio of 0.22. The company has a market cap of $4.72 billion, a P/E ratio of 11.05, a P/E/G ratio of 0.54 and a beta of 0.47. The business has a 50-day simple moving average of $24.35 and a 200-day simple moving average of $26.15.
Institutional Trading of Alkermes
Hedge funds and other institutional investors have recently bought and sold shares of the business. McGlone Suttner Wealth Management Inc. acquired a new position in Alkermes in the 4th quarter valued at about $30,000. GAMMA Investing LLC acquired a new stake in shares of Alkermes during the 4th quarter worth $35,000. Hexagon Capital Partners LLC increased its holdings in shares of Alkermes by 3,841.0% during the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock worth $37,000 after buying an additional 1,498 shares during the last quarter. Daiwa Securities Group Inc. boosted its position in Alkermes by 166.4% during the 4th quarter. Daiwa Securities Group Inc. now owns 1,761 shares of the company’s stock worth $49,000 after purchasing an additional 1,100 shares during the period. Finally, CWM LLC boosted its position in Alkermes by 92.8% during the 4th quarter. CWM LLC now owns 1,999 shares of the company’s stock worth $55,000 after purchasing an additional 962 shares during the period. 95.21% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on Alkermes
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Recommended Stories
- Five stocks we like better than Alkermes
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What is Insider Trading? What You Can Learn from Insider Trading
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Why Are Stock Sectors Important to Successful Investing?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.